Yesterday in Seattle, Dr. Samarendra Mohanty made a presentation on Mutation-Agnostic Vision Restoration in Patients with Retinal Degenerative and participated in a panel discussion on regenerative medicine as part of Ophthalmology Innovation Source Retina Innovation Summit. It was a great opportunity to reconnect with colleagues and meet new people who are working in this important area of research. Today (Sunday 5/5) team Nanoscope Therapeutics Inc. takes part in the opening of #ARVO24. Stop by to meet our leadership team at our booth #4620. We look forward to saying hello as we all kick off a busy week.
Monday 5/6, the first of 6 ARVO presentations featuring our MCO-010 optogenetic therapy for retinitis pigmentosa begin with one by Dr. Allen Ho where he will present 12-month results from our Phase 2b/3 RESTORE clinical trial. Details for all presentations are below and on our website: nanostherapeutics.com
Longitudinal BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: 12-month results from a Phase 2b/3 randomized, sham-controlled, patient- and assessor-masked clinical trial (RESTORE)
Presentation Number: 2137 - Paper Session
May 6, 2024. -- 4:15 – 4:30 p.m. PT
612 - Seattle Convention Center - Arch Building
Presenter: Allen Ho, MD, Chief Medical Advisor
Test-retest Agreement of the Freiburg Visual Acuity Test in Ultra-low Vision
Poster Number: A0223
Type: Poster Session
May 7, 2024 -- 1:15 – 3:00 p.m. PT
Exhibit Hall - Seattle Convention Center
Presenter: Samuel B Barone, MD, CMO
Longitudinal BCVA Analysis of Patients with Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT)
Poster Number: B0094
May 8, 2024 -- 2:15 – 4:00 p.m. PT
Exhibit Hall - Seattle Convention Center
Presenter: Vinit B. Mahajan, MD, PhD, Professor of Ophthalmology, Stanford University
Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in mouse models of retinitis pigmentosa
Abstract/Poster Number: B0293
May 8, 2024 -- 2:15 – 4:00 p.m. PT
Exhibit Hall - Seattle Convention Center
Presenter: Subrata Batabyal, PhD, Director, Non-Clinical Development
Characterization of a Broadband Ambient Light Activatable Multi-Characteristic Opsin Supporting its Superior Performance in Restoring Vision
Poster Number: B0924
Session Date: May 9, 2024 -- 8:00 – 9:45 a.m. PT
Exhibit Hall - Seattle Convention Center
Presenter: Samarendra Mohanty, PhD, President and CSO
In Vivo Efficacy of a Novel Multi-Characteristic Opsin (MCO-010) in a Mouse Model of Leber Congenital Amaurosis
Poster Number: B0942
May 9, 2024 -- 8:00 – 9:45 a.m. PT
Exhibit Hall - Seattle Convention Center
Presenter: Naj Sharif, PhD, DSC, VP of Global Research and Development
Sulagna Bhattacharya #ophthalmology #retina #clinicaltrials